Clinical research suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could increase efficacy.

Promising Biomarker Reductions: Treatment with the MDM2 inhibitor navtemadlin led to significant reductions in key biomarkers of disease severity, including circulating CD34+ cells, a hallmark of ...

Myelofibrosis causes anemia, splenomegaly, and other symptoms, creating unmet treatment needs. The POIESIS trial explores navtemadlin as an add-on to Jakafi for suboptimal responders. Navtemadlin ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis ...

Gemcitabine-docetaxel in patients with relapsed high-grade osteosarcoma after first-line treatment with high-dose ifosfamide: A retrospective multicenter study. This is an ASCO Meeting Abstract from ...

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with Kartos Therapeutics, ...

Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, ...

Dana-Farber Cancer Institute authors: Veronica Rendo, PhD, Eudocia Q. Lee, MD, MPH, Veronica Rendo, PhD Patrick Y. Wen, MD, Keith L. Ligon, MD, PhD, Rameen Beroukhim ...